Endonovo Therapeutics Enters into $10 million Common Stock Purchase Agreement with Azure Capital
January 03, 2019 11:10 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease
November 01, 2018 07:00 ET
|
Breathtec Biomedical Inc.
Planning Phase II Trial VANCOUVER, B.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors
September 06, 2018 07:30 ET
|
Metacrine, Inc.
SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the...
Non-alcoholic Steatohepatitis Biomarkers Market to reach a valuation of US$1.7 bn by 2024, Says TMR
July 31, 2018 09:49 ET
|
Transparency Market Research
Albany, NY, July 31, 2018 (GLOBE NEWSWIRE) -- According to the market research study by Transparency Market Research, in 2016, the global market for NASH biomarkers was worth US$201.2 mn and is...
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
June 13, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine Completes $65 Million Series C Financing
June 06, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018
May 31, 2018 16:05 ET
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present at Jefferies 2018 Global Healthcare Conference
May 31, 2018 07:30 ET
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine Broadens Management Team with Two Key Hires
April 17, 2018 08:00 ET
|
Metacrine
SAN DIEGO, April 17, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
April 02, 2018 10:20 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2018 (GLOBE NEWSWIRE) --
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that...